Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/...

Full description

Bibliographic Details

Main Authors:	Andrea Giacomelli, Federico Conti, Laura Pezzati, Letizia Oreni, Anna Lisa Ridolfo, Valentina Morena, Cecilia Bonazzetti, Gabriele Pagani, Tiziana Formenti, Massimo Galli, Stefano Rusconi
Format:	Artigo
Language:	Inglês
Published:	BMC 2021-06-01
Series:	BMC Infectious Diseases
Subjects:	Single tablet regimens Tenofovir alafenamide Framingham score Cholesterol Cardiovascular risk Integrase inhibitors
Online Access:	https://doi.org/10.1186/s12879-021-06304-3
Tags:	Add Tag No Tags, Be the first to tag this record!